PGEN - Precigen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Germantown,
United States
Type: Equity
PGEN price evolution
PGEN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9.35 | $17.48 | $7.58 | |
| Short term investments | $10.19 | $27.28 | $55.28 | |
| Net receivables | $0.73 | $1.02 | $1.16 | $1.57 |
| Inventory | ||||
| Total current assets | $34.51 | $23.71 | $49.55 | $68.75 |
| Long term investments | ||||
| Property, plant & equipment | $18.84 | $19 | $19.28 | $14.21 |
| Goodwill & intangible assets | $30.01 | $65.27 | $67.31 | |
| Total noncurrent assets | $49.45 | $85.3 | $82.29 | |
| Total investments | $10.19 | $27.28 | $55.28 | |
| Total assets | $83.47 | $73.16 | $134.85 | $151.04 |
| Current liabilities | ||||
| Accounts payable | $4.32 | $4.85 | $4.72 | $1.73 |
| Deferred revenue | $2.2 | $2.29 | $2.33 | |
| Short long term debt | $1.27 | $1.32 | $1.2 | |
| Total current liabilities | $21.22 | $23.02 | $28.77 | $22.98 |
| Long term debt | $5.07 | $5.39 | $5.89 | |
| Total noncurrent liabilities | $6.97 | $9.05 | $9.56 | |
| Total debt | $6.34 | $6.71 | $7.1 | |
| Total liabilities | $28.1 | $29.99 | $37.83 | $32.55 |
| Shareholders' equity | ||||
| Retained earnings | -$2070.98 | -$2047 | -$1988.21 | -$1964.47 |
| Other shareholder equity | -$2.91 | -$2.8 | -$1.95 | |
| Total shareholder equity | $43.17 | $97.02 | $118.5 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.58 | $48.2 | $42.92 | $51.79 |
| Short term investments | $55.28 | $51.09 | $72.24 | $48.33 |
| Net receivables | $1.57 | $13.8 | $21.47 | $16.74 |
| Inventory | $0.29 | $13.26 | $11.36 | |
| Total current assets | $68.75 | $118.16 | $156.63 | $148.95 |
| Long term investments | $48.56 | |||
| Property, plant & equipment | $14.21 | $15.41 | $45.22 | $44.28 |
| Goodwill & intangible assets | $67.31 | $81.38 | $108.26 | $119.76 |
| Total noncurrent assets | $82.29 | $97.82 | $203.23 | $165.64 |
| Total investments | $55.28 | $51.09 | $120.8 | $48.33 |
| Total assets | $151.04 | $215.98 | $359.86 | $314.59 |
| Current liabilities | ||||
| Accounts payable | $1.73 | $4.07 | $5.43 | $4.62 |
| Deferred revenue | $2.33 | $1.84 | $27.46 | $25.82 |
| Short long term debt | $1.2 | $44.43 | $1.95 | $3.02 |
| Total current liabilities | $22.98 | $78.64 | $34.65 | $42.13 |
| Long term debt | $5.89 | $6.99 | $192.25 | $179.27 |
| Total noncurrent liabilities | $9.56 | $11.07 | $217.86 | $205.29 |
| Total debt | $7.1 | $51.42 | $194.2 | $182.28 |
| Total liabilities | $32.55 | $89.72 | $252.51 | $247.41 |
| Shareholders' equity | ||||
| Retained earnings | -$1964.47 | -$1868.57 | -$1915.56 | -$1823.39 |
| Other shareholder equity | -$1.95 | -$2.73 | $0.2 | $4 |
| Total shareholder equity | $118.5 | $126.26 | $107.35 | $67.17 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.95 | $0.72 | $1.06 | $1.23 |
| Cost of revenue | $1.01 | $1.07 | $1.36 | |
| Gross Profit | -$0.06 | -$0.3 | -$0.01 | -$0.13 |
| Operating activities | ||||
| Research & development | $15.69 | $14.25 | $12.99 | |
| Selling, general & administrative | $10.31 | $10.15 | $10.27 | |
| Total operating expenses | $21.21 | $60.54 | $24.4 | $34.09 |
| Operating income | -$60.84 | -$24.41 | -$34.22 | |
| Income from continuing operations | ||||
| EBIT | -$60.48 | -$23.77 | -$33.38 | |
| Income tax expense | $0.01 | -$1.69 | -$0.03 | -$0.33 |
| Interest expense | $0.28 | $0 | $0 | $0.01 |
| Net income | ||||
| Net income | -$23.98 | -$58.79 | -$23.74 | -$33.06 |
| Income (for common shares) | -$58.79 | -$23.74 | -$33.06 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.22 | $26.91 | $103.87 | $103.18 |
| Cost of revenue | $6.12 | $6.34 | $58.38 | $55.51 |
| Gross Profit | $0.11 | $20.57 | $45.49 | $47.66 |
| Operating activities | ||||
| Research & development | $48.61 | $47.17 | $50.14 | $41.64 |
| Selling, general & administrative | $40.41 | $48.01 | $74.12 | $91.7 |
| Total operating expenses | $99.86 | $94.76 | $125.14 | $134.43 |
| Operating income | -$99.76 | -$74.19 | -$79.65 | -$86.77 |
| Income from continuing operations | ||||
| EBIT | -$95.89 | $34.9 | -$73.44 | -$152.2 |
| Income tax expense | -$0.46 | -$0.19 | -$0.16 | -$0.08 |
| Interest expense | $0.47 | $6.77 | $18.89 | $18.4 |
| Net income | ||||
| Net income | -$95.9 | $28.32 | -$92.17 | -$170.52 |
| Income (for common shares) | -$95.9 | $28.32 | -$92.17 | -$170.52 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$58.79 | -$23.74 | -$33.06 | |
| Operating activities | ||||
| Depreciation | $1.6 | $1.59 | $1.61 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.96 | $2.58 | $2.26 | |
| Total cash flows from operations | -$23.11 | -$14.09 | -$15.77 | |
| Investing activities | ||||
| Capital expenditures | -$2.32 | -$4.35 | -$1.01 | |
| Investments | $17.28 | $28.39 | $14.3 | |
| Total cash flows from investing | $44.65 | $14.96 | $24.05 | $13.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | |||
| Net borrowings | ||||
| Total cash flows from financing | $32.18 | $0.05 | ||
| Effect of exchange rate | -$0.03 | -$0.04 | -$0.06 | -$0.01 |
| Change in cash and equivalents | $16.88 | -$8.13 | $9.89 | -$2.49 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$95.9 | $28.32 | -$92.17 | -$170.52 |
| Operating activities | ||||
| Depreciation | $6.67 | $10.77 | $13.76 | $17.52 |
| Business acquisitions & disposals | $162.31 | $64.24 | ||
| Stock-based compensation | $9.89 | $10.21 | $13.9 | $18.37 |
| Total cash flows from operations | -$66.93 | -$65.05 | -$55.77 | -$77.02 |
| Investing activities | ||||
| Capital expenditures | -$1.44 | -$4.33 | -$4.24 | -$1.04 |
| Investments | -$1.65 | $68.44 | -$70.3 | -$35.42 |
| Total cash flows from investing | -$3.09 | $226.42 | -$74.54 | $27.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $72.81 | $0 | $121.65 | $35.12 |
| Net borrowings | -$43.22 | -$155.29 | -$0.47 | -$2.41 |
| Total cash flows from financing | $29.59 | -$155.29 | $121.19 | $32.7 |
| Effect of exchange rate | -$0.32 | -$0.83 | $0.22 | $0.35 |
| Change in cash and equivalents | -$40.75 | $5.25 | -$8.91 | -$16.18 |
News
Fundamentals
| Market cap | $374.87M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 292.87M |
| Revenue | $3.96M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$139.56M |
| Revenue Q/Q | -30.89% |
| Revenue Y/Y | -41.38% |
| P/E ratio | -2.69 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 94.59 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.48 |
|---|---|
| ROA | -126.15% |
| ROE | N/A |
| Debt/Equity | 0.27 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.63 |
| Quick ratio | N/A |